A Meta-Analysis of Randomized Controlled Trials Comparing Chemotherapy Plus Trastuzumab with Chemotherapy Alone in HER-2-Positive Advanced Breast Cancer

被引：6
|
作者：
Liao, Cun [1 ]
Yin, Fang [1 ]
Huang, Ping [1 ]
Cao, Yunfei [1 ]
Gao, Feng [1 ]
机构：
[1] Guangxi Med Univ, Affiliated Hosp 1, Dept Colorectal & Anal Surg, Nanning, Guangxi, Peoples R China
来源：
BREAST JOURNAL | 2011年 / 17卷 / 01期
关键词：
PHASE-II TRIAL; PACLITAXEL; THERAPY;
D O I：
10.1111/j.1524-4741.2010.01034.x
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：109 / 111
页数：3
相关论文
共 50 条
  • [1] A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer
    Yunfei Cao
    Aihua Tan
    Feng Gao
    Lidan Liu
    Cun Liao
    Zengnan Mo
    [J]. International Journal of Colorectal Disease, 2009, 24 : 677 - 685
  • [2] A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer
    Cao, Yunfei
    Tan, Aihua
    Gao, Feng
    Liu, Lidan
    Liao, Cun
    Mo, Zengnan
    [J]. INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2009, 24 (06) : 677 - 685
  • [3] Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials
    Gustavo A Viani
    Sergio L Afonso
    Eduardo J Stefano
    Ligia I De Fendi
    Francisco V Soares
    [J]. BMC Cancer, 7
  • [4] Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials
    Viani, Gustavo A.
    Afonso, Sergio L.
    Stefano, Eduardo J.
    De Fendi, Ligia I.
    Soares, Francisco V.
    [J]. BMC CANCER, 2007, 7 (1)
  • [5] Dual block versus single agent trastuzumab plus chemotherapy as neoadjuvant treatment of HER2-positive breast cancer: a meta-analysis of randomized trials
    Clavarezza, M.
    Puntoni, M.
    Gennari, A.
    Paleari, L.
    Provinciali, N.
    D'Amico, M.
    Decensi, A.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [6] Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials
    Solinas, C.
    Ceppi, M.
    Lambertini, M.
    Scartozzi, M.
    Buisseret, L.
    Garaud, S.
    Fumagalli, D.
    de Azambuja, E.
    Salgado, R.
    Sotiriou, C.
    Willard-Gallo, K.
    Ignatiadis, M.
    [J]. CANCER TREATMENT REVIEWS, 2017, 57 : 8 - 15
  • [7] Chemotherapy plus multitargeted antiangiogenic tyrosine kinase inhibitors or chemotherapy alone in advanced NSCLC: a meta-analysis of randomized controlled trials
    Yong-Ying Xiao
    Ping Zhan
    Dong-Mei Yuan
    Hong-Bing Liu
    Tang-Feng Lv
    Yong Song
    Yi Shi
    [J]. European Journal of Clinical Pharmacology, 2013, 69 : 151 - 159
  • [8] Chemotherapy plus multitargeted antiangiogenic tyrosine kinase inhibitors or chemotherapy alone in advanced NSCLC: a meta-analysis of randomized controlled trials
    Xiao, Yong-Ying
    Zhan, Ping
    Yuan, Dong-Mei
    Liu, Hong-Bing
    Lv, Tang-Feng
    Song, Yong
    Shi, Yi
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 69 (02) : 151 - 159
  • [9] Early and late outcomes of bevacizumab plus chemotherapy versus chemotherapy alone as a neoadjuvant treatment in HER2-negative nonmetastatic breast cancer: a meta-analysis of randomized controlled trials
    Wei, Jinli
    Luo, Yulin
    Fu, Deyuan
    [J]. ONCOTARGETS AND THERAPY, 2018, 11 : 9049 - 9059
  • [10] Trastuzumab combined chemotherapy for the treatment of HER2-positive advanced gastric cancer: A systematic review and meta-analysis of randomized controlled trial
    Xue, Chuan
    Xu, Yong-Hong
    [J]. MEDICINE, 2022, 101 (34) : E29992
12345